Suppr超能文献

治疗初治患者的乙型肝炎急性重度发作合并聚合酶基因耐药突变。

Severe acute hepatitis B in a treatment-naïve patient with antiviral drug resistant mutations in the polymerase gene.

机构信息

Department of Medicine, DIMED, University of Padova, Italy.

出版信息

J Med Virol. 2013 Feb;85(2):210-3. doi: 10.1002/jmv.23448. Epub 2012 Nov 14.

Abstract

This is a case of 62 years old Caucasian treatment-naïve patient who developed a severe acute hepatitis B infection soon after a trip to Thailand. The infection was due to genotype C HBV which was found to be resistant to lamivudine and telbivudine. The patient was treated with tenofovir resulting in complete suppression of viral replication and complete clinical and laboratory remission of acute hepatitis. Later the patient also developed seroconversion of HBeAg to anti-HBe and of HBsAg to anti-HBs. This case demonstrates that mutations of HBV polymerase associated with lamivudine, telbivudine, and adefovir resistance can be present also in untreated patients with severe acute hepatitis B. This suggests that in the clinical context, which represents a life threatening condition, a baseline resistance-testing should be an additional marker in the diagnostic evaluation process. Finally, this case report seems to support the use of tenofovir for the immediate treatment of severe acute hepatitis B.

摘要

这是一位 62 岁的高加索裔初治患者,在泰国旅行后不久即发生严重急性乙型肝炎感染。感染是由基因型 C HBV 引起的,该病毒对拉米夫定和替比夫定具有耐药性。患者接受了替诺福韦治疗,导致病毒复制完全抑制和急性肝炎的临床和实验室完全缓解。后来,该患者还发生了 HBeAg 向抗-HBe 和 HBsAg 向抗-HBs 的血清学转换。本病例表明,与拉米夫定、替比夫定和阿德福韦耐药相关的 HBV 聚合酶突变也可能存在于未经治疗的严重急性乙型肝炎患者中。这表明,在危及生命的临床情况下,基线耐药检测应该是诊断评估过程中的一个附加标志物。最后,本病例报告似乎支持使用替诺福韦立即治疗严重急性乙型肝炎。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验